Successful Treatment of a Pediatric Neurotrophic Keratopathy With Cenegermin

被引:9
|
作者
Papadopoulos, Kosmas [1 ]
Besgen, Volker [1 ]
Sekundo, Walter [1 ]
机构
[1] Philipps Univ Marburg, Fac Med, Dept Ophthalmol, Baldingerstr, D-35043 Marburg, Germany
关键词
cenegermin; pediatric neurotrophic keratopathy; child; cornea; OUTCOMES;
D O I
10.1097/ICO.0000000000002512
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: We present a challenging case of a 9-year-old patient with refractory neurotrophic keratopathy (NK) who was successfully treated with cenegermin eye drops. Methods: A 7-year-old boy developed an ocular infection after a visit to a public swimming pool. After having been unsuccessfully treated for 2 years with antibiotics, steroids, and artificial tears, the patient presented to our clinic with a therapy-refractory NK. We initiated treatment with autologous serum eye drops that showed only weak response. Therefore, treatment with cenegermin eye drops was started. Results: After cenegermin therapy, a complete restoration of the corneal surface and an increase in visual acuity were achieved. Conclusions: The use of cenegermin is effective in treating pediatric NK.
引用
收藏
页码:516 / 518
页数:3
相关论文
共 50 条
  • [41] Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy
    Pavan-Langston, Deborah
    Dohman, Claes H.
    OPHTHALMOLOGY, 2008, 115 (02) : S21 - S23
  • [42] Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy
    Reza Dana
    Marjan Farid
    Preeya K. Gupta
    Pedram Hamrah
    Paul Karpecki
    Cathleen M. McCabe
    Lisa Nijm
    Jay S. Pepose
    Stephen Pflugfelder
    Christopher J. Rapuano
    Arvind Saini
    Sarah N. Gibbs
    Michael S. Broder
    BMC Ophthalmology, 21
  • [43] Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy A Multicenter Randomized Vehicle-Controlled Pivotal Trial
    Pflugfelder, Stephen C.
    Massaro-Giordano, Mina
    Perez, Victor L.
    Hamrah, Pedram
    Deng, Sophie X.
    Espandar, Ladan
    Foster, C. Stephen
    Affeldt, John
    Seedor, John A.
    Afshari, Natalie A.
    Chao, Wendy
    Allegretti, Marcello
    Mantelli, Flavio
    Dana, Reza
    OPHTHALMOLOGY, 2020, 127 (01) : 14 - 26
  • [44] Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
    Pedram Hamrah
    Mina Massaro-Giordano
    David Schanzlin
    Edward Holland
    Gregg Berdy
    Giovanni Goisis
    Georgea Pasedis
    Flavio Mantelli
    Ophthalmology and Therapy, 2024, 13 : 553 - 570
  • [45] Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy
    Hamrah, Pedram
    Yavuz Saricay, Leyla
    Ozmen, M. Cuneyt
    CORNEA, 2022, 41 (06) : 673 - 679
  • [46] Successful treatment of diabetic keratopathy with punctal occlusion
    Sakamoto, A
    Sasaki, H
    Kitagawa, K
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2004, 82 (01): : 115 - 117
  • [47] Treatment of Limbal Stem Cell Deficiency in the Setting of Neurotrophic Keratopathy
    Hristova, Rozaliya
    Zdravkov, Yani
    Hristova, Maria
    Tanev, Ivan
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2020, 8 (02): : 30 - 37
  • [48] Nerve Growth Factor Treatment for Neurotrophic Keratopathy in the IRIS® Registry
    Zidan, Asmaa A.
    Gilbert, Joshua B.
    Goldberg, Eric
    Ross, Connor
    Elze, Tobias
    Lorch, Alice C.
    Miller, Joan W.
    Dana, Reza
    Yin, Jia
    OPHTHALMOLOGY, 2025, 132 (03) : 368 - 370
  • [49] Neurotrophic Keratopathy in the United States
    Bian, Yandong
    K, Kevin
    Hall, Nathan E.
    Elze, Tobias
    Lorch, Alice
    Miller, Joan W.
    Dana, Reza
    Yin, Jia
    OPHTHALMOLOGY, 2022, 129 (11) : 1255 - 1262
  • [50] Surgical management of neurotrophic keratopathy
    Shortt, Alex
    ACTA OPHTHALMOLOGICA, 2019, 97